TY - JOUR
T1 - COVID-19 as an acute inflammatory disease
AU - Manjili, Rose H.
AU - Zarei, Melika
AU - Habibi, Mehran
AU - Manjili, Masoud H.
N1 - Funding Information:
This work was supported by pilot funding from the VCU Massey Cancer Center (to M.H.M.) and supported in part by National Institutes of Health National Cancer Institute Cancer Center Support Grant P30 CA016059.
Funding Information:
We thank the VCU Massey Cancer Center and the Commonwealth Foundation for Cancer Research for support.
Publisher Copyright:
Copyright Ó 2020 by The American Association of Immunologists, Inc. 0022-1767/20/$37.50
PY - 2020/7/1
Y1 - 2020/7/1
N2 - The 2019 coronavirus disease (COVID-19) pandemic caused by the virus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has created an unprecedented global crisis for the infrastructure sectors, including economic, political, healthcare, education, and research systems. Although over 90% of infected individuals are asymptomatic or manifest noncritical symptoms and will recover from the infection, those individuals presenting with critical symptoms are in urgent need of effective treatment options. Emerging data related to mechanism of severity and potential therapies for patients presenting with severe symptoms are scattered and therefore require a comprehensive analysis to focus research on developing effective therapeutics. A critical literature review suggests that the severity of SARS-CoV-2 infection is associated with dysregulation of inflammatory immune responses, which in turn inhibits the development of protective immunity to the infection. Therefore, the use of therapeutics that modulate inflammation without compromising the adaptive immune response could be the most effective therapeutic strategy.
AB - The 2019 coronavirus disease (COVID-19) pandemic caused by the virus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has created an unprecedented global crisis for the infrastructure sectors, including economic, political, healthcare, education, and research systems. Although over 90% of infected individuals are asymptomatic or manifest noncritical symptoms and will recover from the infection, those individuals presenting with critical symptoms are in urgent need of effective treatment options. Emerging data related to mechanism of severity and potential therapies for patients presenting with severe symptoms are scattered and therefore require a comprehensive analysis to focus research on developing effective therapeutics. A critical literature review suggests that the severity of SARS-CoV-2 infection is associated with dysregulation of inflammatory immune responses, which in turn inhibits the development of protective immunity to the infection. Therefore, the use of therapeutics that modulate inflammation without compromising the adaptive immune response could be the most effective therapeutic strategy.
UR - http://www.scopus.com/inward/record.url?scp=85086916173&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086916173&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.2000413
DO - 10.4049/jimmunol.2000413
M3 - Review article
C2 - 32423917
AN - SCOPUS:85086916173
SN - 0022-1767
VL - 205
SP - 12
EP - 19
JO - Journal of Immunology
JF - Journal of Immunology
IS - 1
ER -